Detect aggregation before yield and product quality are compromised

Protein concentration, buffer composition, and aggregation propensity can change rapidly — yet most process monitoring and process control strategies still rely on extractive, delayed analytics. During UF/DF, proteins are exposed to high local concentrations, shear forces, and rapid buffer exchange, all of which increase the risk of aggregation precisely at a stage where material value is at its highest.

As upstream processes intensify, downstream purification windows narrow. Waiting for off‑line results means:

• Aggregation issues are detected after yield is already lost
• UF/DF runs are paused unnecessarily
• Corrective actions are applied too late to be effective

The result is fragmented downstream workflows, longer cycle times, and increased risk to product quality. Because UF/DF occurs late in downstream processing, aggregation detected after completion often results in irreversible yield loss, rework, or batch rejection, rather than simple parameter adjustment.

Conventional real-time measurements during UF/DF do not indicate whether aggregation is developing, or whether buffer exchange is truly complete. This understanding is only available through offline analysis, not in real time. Inline Raman spectroscopy analysis – a process analytical technology (PAT) – integrated into the UF/DF flow path, provides continuous, non‑extractive insight into the purification process as it unfolds.

Instead of inferring process state from pressure, flow, or volume alone, teams gain direct visibility into:

• Protein concentration evolution during UF and final concentration
• Buffer exchange progression during diafiltration
• Spectral signatures associated with aggregation behavior

This distinction is critical, because product quality attributes evolve independently of hydraulic stability during UF/DF.

When downstream insight is available during UF/DF, decisions move upstream in time. If aggregation‑related spectral trends emerge inline, teams can still adjust concentration rates, modify diafiltration buffer exchange, or halt the process before final concentration, rather than discovering the issue later by off‑line analytical methods like size-exclusion chromatography (SEC).

By implementing a versatile PAT that delivers highly specific, multi-analyte process insight in real time, teams no longer wait for post‑process confirmation to understand what happened. They can:

• Detect early aggregation trends while the UF/DF run is still recoverable, enabling mitigation before yield or quality is irreversibly impacted
• Adjust operating conditions while the process is still running
• Avoid unnecessary process interruptions
• Shorten development cycles by reducing rework and repeat runs

Teams applying inline Raman spectroscopy during UF/DF can document tangible downstream improvements, including:

• Reduced UF/DF cycle times by eliminating analytical wait periods
• Lower product loss through earlier aggregation detection
• Improved batch consistency across biosimilar production runs
• Less manual intervention and fewer post‑process adjustments
• Faster DSP development enabled by PAT‑ready process understanding

Beyond yield, earlier visibility into aggregation protects drug substance efficacy, pharmacokinetics, immunogenicity risk, and regulatory acceptability — all of which are directly influenced by aggregate levels in biopharmaceutical products. These benefits compound across campaigns, reducing cost of goods and accelerating time to market.

Endress+Hauser supports downstream and PAT teams from process understanding through model development and deployment, helping translate Raman spectroscopy capability into decision‑grade UF/DF workflows.

The focus is not on instrumentation alone, but on enabling earlier intervention, higher yield protection, and more resilient downstream processes in biopharmaceutical manufacturing.